All In Biotech

Drug Trial Radar · NCT01580878

Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis

A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Butenafine Hydrochloride Cream, 1% and Reference Listed Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Interdigital Tinea Pedis.

Last checked: Nov 19, 2026Latest source record: May 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 707 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

707

Actual

Start

Jan 2012

Primary completion

Aug 2012

Study completion Dec 2012

Sponsor

Sponsor type
Industry
First posted
Apr 19, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the comparability of the safety and efficacy of a generic Butenafine Hydrochloride Cream, 1% (test product) and Lotrimin Ultra® (the reference listed drug) in subjects with interdigital tinea pedis. It will also be determined whether the efficacy of each of the two active treatments is superior to that of the vehicle cream (placebo).

Conditions

  • Tinea Pedis

Interventions

  • Butenafine Hydrochloride Cream, 1%Drug

    Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days

  • Lotrimin Ultra®Drug

    Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.

  • Butenafine VehicleDrug

    Butenafine Vehicle applied twice daily for 7 consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Therapeutic CureTime frame: 42 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.